Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)

This program is supported by Abbvie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hilton Orlando , Orange Ballroom

This activity, the first of a 2-part series, will attempt to address many of the most common practical issues encountered by clinicians managing patients with non-Hodgkin lymphomas as well as chronic lymphocytic leukemia (CLL). To accomplish this goal, prior to the event RTP will recruit 6 general hematologic oncologists to serve as the project’s Planning Committee. These individuals will participate in a closed planning session at RTP headquarters during which a number of key questions, issues and challenging cases from their practices will be discussed. With this information providing the basis for the agenda, the meeting, which will feature 6 renowned lymphoma/CLL investigators serving as the faculty, will employ a blend of short didactic presentations, interactive audience polling using networked iPads and extensive moderated panel discussion to provide perspectives on new and emerging research and address many of the real-world concerns voiced by the Planning Committee members. A video-recorded capture of the program will be distributed as an enduring CME resource to deliver the valuable and practical information that emerges to a larger worldwide audience.

Chair:

Neil Love , MD, Research To Practice, Miami, FL

Speakers:

Jeremy S. Abramson , MD, MMSc , Massachusetts General Hospital Cancer Center , Boston,  MA

Bruce D. Cheson , MD , Georgetown University Hospital , Washington,  DC

Professor John G. Gribben , MD, DSc , Barts Cancer Institute, Queen Mary University of London , London,  United Kingdom

Brad S. Kahl , MD , Washington University , St Louis,  MO

Loretta J. Nastoupil , MD, MSc , The University of Texas MD Anderson Cancer Center , Houston,  TX

Laurie H Sehn , MD , British Columbia Cancer Agency , Vancouver,  BC, Canada

Contact:

Sylvia Eriksen , Research To Practice
Email: seriksen@researchtopractice.com

Registration:

http://www.researchtopractice.com/Meetings/FSS2019

Advances in Hemophilia A: Expert Guidance and Practical Case Discussions

This program is supported by Genentech

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Regency O-Q

This interactive symposium will feature guidance and perspective on expert strategies and therapeutic decisions for patients with hemophilia A. New insights include a look ahead at new data and promising agents that may soon change practice.

 

Renowned hemophilia experts— Guy Young, MD; Stacy Croteau, MD, MMS; Michael Callaghan, MD; and Cindy Leissinger, MD—will discuss the evidence behind current best practice management strategies, both with and without inhibitors, for patients with hemophilia A requiring prophylaxis.

 

The program will include patient case challenges and reflection on considerations that impact therapeutic decisions. Recent clinical trial data and ongoing trials of novel therapeutic approaches will be presented, including antithrombin inhibitor, anti-TFPI antibodies, and gene therapy, with a focus on how these agents may affect management strategies for patients with hemophilia A in the near future.

 

Throughout the symposium, attendees will interact with experts through interactive case challenges and polling questions, as well as by texting questions directly to the panel for their consideration.

 

Discussion topics include:

- Current clinical progress/unmet needs in hemophilia A

-New developments in factor and nonfactor replacement strategies

-Implementing an individualized care approach

-Clinical challenges in applying new evidence to practice

-Review of rationale/efficacy and safety data for emerging therapies and ongoing clinical trials

Chair:

Guy Young , MD, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA

Speakers:

Michael Callaghan , MD , Wayne State University , Detroit,  MI

Stacy E. Croteau , Children's Hospital Boston , Boston,  MA

Cindy A. Leissinger , MD , Tulane University School of Medicine , New Orleans,  LA

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

http://www.clinicaloptions.com/2019OrlandoHemophilia

Advancing Science in Sickle Cell Disease: Implications for the Future of Care

This program is supported by Novartis

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hilton Orlando , Orlando Ballroom 1

Sickle cell disease (SCD) is a debilitating, inherited condition that affects about 100,000 individuals in the United States. While it is a molecularly well-characterized disease, there are few treatments available and less than one-third of eligible patients receive standard of care. Fortunately, recent years have brought an explosion in therapeutic advances regarding the management of patients with SCD, including, but not limited to gene therapy, novel drug targets, and new clinically meaningful endpoints. Moreover, an increased understanding of disease state and phenotypes is leading to evolving management recommendations. With these advances, providers will require education by global leading experts on these advances and implications for clinical practice.

Chair:

Kenneth I. Ataga , MBBS, University of Tennessee Health Science Center at Memphis, Memphis, TN

Speakers:

Jo Howard , MB, BChir , Guy's and St. Thomas' NHS Foundation Trust , London,  United Kingdom

Julie Kanter , MD , Director of the UAB Adult Sickle Cell Clinic Associate Professor in the Division of Hematology and Oncology , Birmingham,  AL

Mark C. Walters , MD , UCSF Benioff Children's Hospital , Oakland,  CA

Contact:

Contact Us , Vindico Medical Education

Registration:

VindicoCME120619pm.eventbrite.com

Approaches To Achieve the Best Possible Outcomes in Myeloma

This program is supported by Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics Inc., Oncopeptides and Takeda Oncology

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Windermere Ballroom

Attendees of this annual International Myeloma Foundation/Clinical Care Options co-sponsored symposium can expect to gain practical insights from a panel of experts as they discuss new therapeutic advances along with their personal approaches for myeloma care. The international panel will focus on evolving worldwide standards of care and will also provide their perspectives on promising agents that may soon change practice.

 

Brian G.M. Durie, MD; Shaji Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD will debate clinical questions, discuss available evidence and challenges that impact therapeutic decisions, and then share their individual treatment recommendations for each case. Throughout the symposium, participants will be able to vote on case scenarios and directly interact with the panel in a dynamic question and answer format. Discussion topics include:

• Diagnosis and Risk Stratification of Plasma Cell Disorders: To Treat or Not to Treat
• Making Upfront Therapy Decisions: Advances in Induction, Autologous Transplantation, Consolidation, and Maintenance Therapy
• The Current Therapeutic Landscape for Relapsed or Refractory MM: Which Combinations to Use and When?
• Future Directions: New and Promising Treatments for MM

Review of 2020 Treatment Algorithm for Multiple Myeloma

Chair:

Brian G.M. Durie , MD, Cedars Sinai Cancer Center, Los Angeles, CA

Speakers:

Shaji K. Kumar , MD , Mayo Clinic , Rochester,  MN

Thomas G. Martin III , MD , University of California, San Francisco , San Francisco,  CA

Philippe Moreau , MD , University Hospital Hôtel-Dieu , Nantes,  France

S. Vincent Rajkumar , MD , Mayo Clinic , Rochester,  MN

Jesús San-Miguel , Clinica Universidad de Navarra, CIMA, IDISNA , Pamplona,  Spain

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

https://www.clinicaloptions.com/2019OrlandoMM

Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders

This program is supported by Alexion Pharmaceuticals, Inc., Rigel Pharmaceuticals, and Sanofi-Aventis U.S.

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Regency T-V

A panel of expert hematologists will review the challenges, opportunities, and key advances in the diagnosis and treatment of rare, non-malignant hematologic conditions such as ITP, aTTP, AIHA, aHUS, and PNH. Using a roundtable format, the faculty will review key data for established, newer, and emerging therapies for these distinct disorders. Case-based presentations will drive discussions focused on assessing the strengths and limitations of available therapies, evaluate how different therapies may be used in patient care to improve outcomes, and highlight key considerations when developing individualized care strategies. Interactive gaming through mobile devices will further engage the audience before and after the symposium by inviting hematologists to test their knowledge and compare their treatment approaches with their colleagues.

Chair:

David J. Kuter, Massachusetts General Hospital, Boston, MA

Speakers:

Ivy Altomare , MD , Duke University School of Medicine , Durham,  NC

Spero Cataland , MD , The Ohio State University , Columbus,  OH

Marie Scully , University College London Hospitals, Cardiometabolic Programme, National Institute for Health Research UCLH-UCL Biomedical Research Center , London,  United Kingdom

Ilene C. Weitz , MD , Keck-USC School of Medicine , Los Angeles,  CA

Contact:

Jae Eising , Medscape Education
Email: jeising@medscape.net

Registration:

www.medscape.org/sympo/rare-heme-disorders

CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia – Clinical Updates and Innovations

This program is supported by Novartis Pharmaceuticals, Legend Biotech

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hilton Orlando , Florida Ballroom 1-4

This interactive symposium will gather 4 experts that utilize CAR T-cell-based therapy for the treatment of patients with hematologic malignancies. They will discuss clinical data of approved and emerging CAR T-cell therapies in patients with lymphoma, myeloma, and leukemia, as well as strategies for mitigating treatment-related adverse events and improving patient outcomes. In addition to clinical data presentations, the symposium will include case reviews, panel discussions, audience Q&A, audience response technology and more. Afterwards, there will also be an associated online enduring activity, with both activities being certified for AMA Category 1 Credit.

Chair:

Julie M Vose , MD MBA, University of Nebraska Medical Center, Omaha, NE

Speakers:

Bruce L Levine , PhD , University of Pennsylvania , Philadelphia,  PA

Frederick L. Locke , MD , Moffitt Cancer Center , Tampa,  FL

David S. Siegel , Hackensack University Medical Center , Hackensack,  NJ

Contact:

Chloe Dunnam , Bio Ascend
Email: dunnam@bioascend.com

Registration:

http://www.cartsymposium.com

Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies

This program is supported by Aplastic Anemia and MDS International Foundation

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Orange County Convention Center , W308, Level 3

The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present the symposium, Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies. This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, AML and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Chair:

Betty K. Hamilton , MD, Cleveland Clinic Foundation, Cleveland, OH

Speakers:

Angela G. Fleischman , MD, PhD , University of California, Irvine , Irvine,  CA

Lukasz P. Gondek , MD,PhD , Johns Hopkins , Baltimore,  MD

Alan F. List , MD , Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute , Tampa,  FL

Uwe Platzbecker , MD , University Hospital Leipzig , Leipzig,  Germany

Phillip Scheinberg , MD , Hospital A Beneficencia Portuguesa , São Paulo,  Brazil

Eytan M. Stein , MD , Memorial Sloan Kettering Cancer Center , New York,  NY

Contact:

Ronna Romano , Cleveland Clinic
Email: romanor@ccf.org

Registration:

www.ccfcme.org/wave19

Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL

This program is supported by MorphoSys AG

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Rosen Centre , Grand Ballroom C

Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL will bring you expert perspectives on managing challenges in treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). You will learn about the disease continuum, including state-of-the-art approaches in risk classification and selection of therapy. Although first-line chemoimmunotherapy is the current standard of care for patients with newly diagnosed DLBCL, approximately half of the patients will experience either disease relapse or refractory disease. Stem-cell transplant plays an important role in the management of these patients; however, many patients are not candidates for transplant due to age, comorbidities, and other factors, creating an unmet medical need. In this activity, you will also learn about cutting-edge approaches in development for transplant-ineligible patients with relapsed/refractory DLBCL, including antibodies targeting novel cell-surface antigens, inhibitors of B-cell receptor signaling, and cellular immunotherapy. Throughout the program, expert discussion panels will illustrate emerging approaches for patients with relapsed/refractory DLBCL, as well as review related abstracts to be presented in Orlando.

Chair:

Gilles A. Salles , MD, PhD, Lyon-Sud University Hospital Complex, Pierre-Bénite, France

Speakers:

Ranjana Advani , MD , Stanford Cancer Institute , Stanford,  CA

Andre H. Goy , MD, MS , John Theurer Cancer Center at Hackensack-UMC , Hackensack,  NJ

Marie José Kersten , MD, PhD , University of Amsterdam , Amsterdam,  Netherlands

Kami J. Maddocks , MD , The James Cancer Hospital at The Ohio State University , Columbus,  OH

Thomas E. Witzig , MD , Mayo Clinic Cancer Center , Rochester,  MN

Contact:

Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com

Registration:

www.gotoper.com/go/DLBCL19

Expert Perspectives on the Role of BTK Inhibitors in CLL

This program is supported by Acerta Pharma - A member of the AstraZeneca Group

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Plaza International D-F

This live, case-based symposium is designed to aid community and academic hematologists/oncologists in applying clinical concepts regarding BTK inhibitors to therapeutic decision making for patients with CLL. Experts will discuss the latest clinical trial data and will offer clinical pearls about selecting patients to receive BTK inhibitors. This education will help clinicians integrate BTK inhibitors into practice and will improve their ability to tailor therapy for patients with CLL based on their individual and disease specific characteristics.

Chair:

Jonathon B. Cohen , MD,MS, Emory University, Atlanta, GA

Speakers:

Danielle M. Brander , MD , Duke University Medical Center , Durham,  NC

Philip A. Thompson , MBBS , The University of Texas MD Anderson Cancer Center , Houston,  TX

Contact:

Erin Kiernan , Medscape Education
Email: ekiernan@medscape.net

Registration:

www.medscape.org/sympo/cll-btk

Medical Crossfire®: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think and Treat

This program is supported by Amgen Inc., Pfizer, Inc., and Takeda Oncology.

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Plaza International H

This Medical Crossfire® will provide an ideal format for you to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda centered on the contemporary management of patients with ALL. You will have the opportunity to absorb the perspectives of leading clinical experts on a variety of different patient scenarios, and to reflect on their handling of these cases as they integrate relevant evidence into real-world practice. You will also be able to compare your patient care approaches with those of the faculty and other participating clinicians. Faculty will discuss factors that may influence risk stratification and treatment decisions, methods to best integrate the latest therapies into ALL treatment paradigms, barriers to optimized integration of these novel agents, and best practices to assist you with the management of adverse events.

Chair:

Elias Jabbour , MD, University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Speakers:

Nicola Gökbuget , MD , Goethe University Hospital , Frankfurt,  Germany

Stephan Grupp , MD, PhD , Children's Hospital of Philadelphia , Philadelphia,  PA

Dieter Hoelzer , MD, PhD , University of Frankfurt , Frankfurt,  Germany

Hagop M. Kantarjian , MD , M.D. Anderson Cancer Center , Houston,  TX

Contact:

Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com

Registration:

www.gotoper.com/go/ALL19

Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges

This program is supported by Sanofi Genzyme

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hilton Orlando , Orlando Ballroom 3

A multi-specialty panel of experts will convene to review the role of MRD in hematologic malignancies, including prognostic factors; distinguishing among types of MRD tests; when to test; and the current understanding of the value of MRD across hematologic malignancies, including MM, ALL, CLL and AML.

Chair:

Gail J. Roboz , MD, Weill Cornell Medicine, New York, NY

Speakers:

Ajai Chari , MD , Mt. Sinai School of Medicine , New York,  NY

Steven Coutre , MD , Stanford University Medical Center , Stanford,  CA

Prashant Kapoor , MD , Mayo Clinic , Rochester,  MN

Aaron C. Logan , MD, PhD , University of California San Francisco , San Francisco,  CA

Contact:

Kelly Jackson , Imedex
Email: k.jackson@imedex.com

Registration:

https://www.naccme.com/program/7335

Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy

This program is supported by BioMarin, Spark Therapeutics and uniQure.

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Rosen Centre , Grand Ballroom AB

Join an international panel of experts to learn the latest data and advances in the development of gene therapy for the treatment of hemophilia. Clinicians will receive guidance about the key considerations for incorporating gene therapy into patient care. Video-based patient stories will provide perspectives on the decision-making process for pursuing gene therapy as a treatment option and the impact on the patient's daily life.

Chair:

Steven Pipe , MD, University of Michigan, Ann Arbor, MI

Speakers:

Wolfgang Miesbach , MD, PhD , Goethe University Hospital , Frankfurt/Main,  Germany

John Pasi , MB, ChB, PhD, FRCP, FRCPath, FRCPCH , Barts and the London School of Medicine and Dentistry , London,  United Kingdom

Thierry VandenDriessche , PhD , Vrije University Brussels , Brussels,  Belgium

Contact:

Charlene Foroutan , Medscape Oncology
Email: cforoutan@medscape.net

Registration:

www.medscape.org/sympo/gene-therapy-hemophilia

New Data and Paradigms in ALL: Insights and Applications

This program is supported by Servier

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Plaza International I-K

This interactive symposium is designed to improve the knowledge and confidence of haematologists/oncologists in applying best practice in the treatment of ALL. The faculty will describe and discuss the very latest data and thinking in the treatment of ALL across the full spectrum of age groups encountered in practice: pediatrics, adolescents/young adults and adults. Specific attention will be placed on discussing the role of asparaginase in treatment protocols in terms of selection and optimal application in practice, including anticipation and appropriate management of asparaginase toxicities and hypersensitivity/silent inactivation. A key overall goal is to address how clinicians can improve on the current treatment of ALL to achieve the best outcomes for patients.

Chair:

Daniel J. DeAngelo, Harvard Medical School, Boston, MA

Speakers:

Dan Douer , MD , University of Southern California , Los Angeles, 

Lewis B. Silverman , MD , Dana-Farber Cancer Institute , Boston,  MA

Wendy Stock , MD , University of Chicago , Chicago,  IL

Contact:

Erin Kiernan , Medscape Education
Email: ekiernan@medscape.net

Registration:

www.medscape.org/sympo/all-evolvingtreatment

New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions

This program is supported by Seattle Genetics and Takeda Oncology

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Regency S

This satellite symposium presents a great opportunity for clinicians to learn about the latest therapeutic advances in peripheral T-cell lymphoma (PTCL). Prior to the live event, this program will include 2 online expert commentaries on the evolving PTCL treatment landscape. At the live symposium, the faculty will review recent advances in PTCL treatment, including biomarker assessment, chemotherapy-based frontline treatments, novel targeted agents, combination therapies, treatment options in the relapsed/refractory (R/R) setting, and provide guidance on individualized therapeutic approaches. A moderated panel discussion and an audience question and answer session will close each section of the symposium and will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice. Symposium participants will be provided with a networked all-in-one handheld device that enables them to fully interact, text, and contribute to the cases discussed by the panel. Throughout the symposium, participants will have the opportunity to directly query the faculty for further clarification of the education or to obtain expert perspectives on their own treatment challenges.

Chair:

Steven M. Horwitz , MD, Memorial Sloan Kettering Cancer Center, New York, NY

Speakers:

Francine M. Foss , MD , Yale University School of Medicine , New Haven,  CT

Barbara Pro , MD , Feinberg School of Medicine, Northwestern University , Chicago,  IL

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

http://www.clinicaloptions.com/2019OrlandoPTCL

Potentiating the Power of Platelets: Examining the Clinical Utility of Multiple Thrombopoietin Receptor Agonists in ITP, Chemotherapy Induced Thrombocytopenia and Liver Disease

This program is supported by Dova Pharmaceuticals

Friday, December 06, 2019, 12:30 p.m. - 3:00 p.m.
Hilton Orlando , Orlando Ballroom 4-6

Advances in understanding the pathophysiology of thrombocytopenia have led to the development of a new class of agent, thrombopoietin receptor agonists (TRAs), two of which were recently approved by the US Food and Drug Administration. These therapies have implications across a range of thrombocytopenias and disease states. TRAs overcome many limitations of the minimally effective conventional procedures used to manage patients with chronic liver disease who undergo elective surgical procedures. TRAs also have implications as first- and second-line treatment strategies in patients with chronic thrombocytopenia, specifically immune thrombocytopenia purpura (ITP), and is emerging as a treatment strategy for chemotherapy-induced thrombocytopenia. Appropriate use of these agents in practice requires that treating clinicians are both up-to-date on the latest evidence-based literature regarding TRAs as part of thrombocytopenia management and proficient in implementing these treatments appropriately. As a result, there is a need for education, specifically for hematologists and other healthcare professionals who treat patients with thrombocytopenia, that focuses on the efficacy and safety of novel treatments, the pathophysiology of hemostatic mechanisms affected in liver disease and other pathologies, bleeding risk laboratory measures used to guide treatment-making decisions, and navigating guideline recommendations for the appropriate diagnosis and treatment strategies for patients with thrombocytopenia.

Chair:

Satish Pramod Shanbhag , MBBS, MPH, Johns Hopkins University School of Medicine, Baltimore, MD

Speaker:

James B. Bussel , MD , Weill Cornell Medicine , New York,  NY

Contact:

Catherine Zehr , ASiM CE LLC
Email: czehr@asimcme.com

Registration:

www.jhasim.com/ASH2019

Primary HLH: Diagnosis, Management, and Treatment in the 21st Century

This program is supported by Swedish Orphan Biovitrum AB

Friday, December 06, 2019, 12:30 p.m. - 3:30 p.m.
Rosen Centre , Grand Ballroom DE

Hemophagocytic lymphohistiocytosis (HLH) is a rare blood disorder mediated by overactivated immune cells. Rare hematologic disorders present a distinct challenge for hematologists and other physicians, and prompt differential diagnosis and initiation of effective treatment are critical to optimizing outcomes for patients with HLH. This satellite symposium will provide physicians who encounter these patients with up-to-date information on the diagnosis, pathobiology, and treatment of primary HLH. The expert faculty panel will review the latest clinical data and ongoing clinical trials with the potential to affect care of patients with HLH. Didactic presentations combined with illustrated case studies will provide the opportunity to apply new information to clinical scenarios, equipping participants with the tools to utilize emerging data to optimize care of their patients with HLH.

Chair:

Michelle L. Hermiston , MD, PhD, University of California San Francisco, Benioff Children's Hospital, San Francisco, CA

Speakers:

Ashish R Kumar , MD, PhD , Cincinnati Children's Hospital Medical Center , Cincinnati,  OH

Kenneth L. McClain , MD, PhD , Texas Childrens Cancer and Hematology Centers , Houston,  TX

Philip A. Roehrs , MD , Carolinas Medical Center , Charlotte,  NC

Contact:

Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com

Registration:

www.gotoper.com/go/HLH19

Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches

This program is supported by GlaxoSmithKline, Oncopeptides and Karyopharm Therapeutics.

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Orlando Ballroom LMN

This live symposium is designed to improve the knowledge of hematologists/oncologists about the evolving multiple myeloma treatment paradigm. Case-based discussion will provide clinical pearls about how to tailor therapy selections for patients with first relapse and multiply relapsed disease. Novel and emerging therapies will also be discussed so providers can effectively integrate these agents into practice when they become available.

Chair:

Ravi Vij , MBBS, Washington University School of Medicine at St. Louis, Ballwin, MO

Speakers:

Christina Gasparetto , MD , Duke Cancer Institute , Durham,  NC

Peter M. Voorhees , MD , Levine Cancer Institute - Morehead (Hematology) , Charlotte,  NC

Contact:

Charlene Foroutan , Medscape Oncology
Email: cforoutan@medscape.net

Registration:

www.medscape.org/sympo/emerging-myeloma

ß-Thalassemia: Expert Insights on New Therapies for an Old Disease

This program is supported by Celgene Corporation

Friday, December 06, 2019, 12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando , Regency R

This live, CME-certified symposium will reveal how experts approach current therapeutic decisions for their patients with ß-thalassemia and provide a look ahead at new data and promising agents that may soon change practice.

 

International ß-thalassemia experts—Maria Domenica Cappellini, MD; Janet L. Kwiatkowski, MD, MSCE; and Sujit Sheth, MD—will discuss evidence behind current best practice management strategies for both transfusion-dependent thalassemia (TDT) and non-TDT, including patient case presentations, their treatment recommendations for each case, and reflection on challenges that impact therapeutic decisions. Recent clinical trial evidence and ongoing clinical trials on novel therapeutic approaches, including erythroid maturation agents and gene therapy with lentiviral vectors, will be presented and discussed, with a focus on how these agents may affect management strategies for patients with ß-thalassemia in the near future.

 

Throughout the symposium, attendees will interact with the experts through case-based challenges and polling questions as well as will be able to text questions directly to the panel for their consideration.

 

Discussion topics include:

-Overview of ß-Thalassemia and Unmet Therapeutic Needs

-Current Management of ß-Thalassemia

-Emerging Biologic Therapies on the Horizon

-The Promise of Gene Therapy in ß-Thalassemia

Chair:

Maria Domenica Cappellini , MD, University of Milan, Milan, Italy

Speakers:

Janet L. Kwiatkowski , MD, MSCE , The Children's Hospital of Philadelphia , Philadelphia,  PA

Sujit Sheth , MD , Cornell University , New York,  NY

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

http://www.clinicaloptions.com/2019OrlandoBetaT

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenström Macroglobulinemia (Part 2 of a 2-Part Series)

This program is supported by Abbvie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hilton Orlando , Orange Ballroom

This activity, the second of a 2-part series, will attempt to address many of the most common practical issues encountered by clinicians managing patients with multiple myeloma (MM), including the related diseases Waldenström macroglobulinemia and amyloidosis. To accomplish this goal, prior to the event RTP will recruit 6 general hematologic oncologists to serve as the project’s Planning Committee. These individuals will participate in a closed planning session at RTP headquarters during which a number of key questions, issues and challenging cases from their practices will be discussed. With this information providing the basis for the agenda, the meeting, which will feature 6 renowned MM investigators serving as the faculty, will employ a blend of short didactic presentations, interactive audience polling using networked iPads and extensive moderated panel discussion to provide perspectives on new and emerging research and address many of the real-world concerns voiced by the Planning Committee members. A video-recorded capture of the program will be distributed as an enduring CME resource to deliver the valuable and practical information that emerges to a larger worldwide audience.

Chair:

Neil Love , MD, Research To Practice, Miami, FL

Speakers:

Jesus G. Berdeja , MD , Sarah Cannon Center For Blood Cancers , Nashville,  TN

Sagar Lonial , MD , Emory University School of Medicine , Atlanta,  GA

Maria-Victoria Mateos , MD, PhD , University Hospital of Salamanca/IBSAL , Salamanca,  Spain

Nikhil C. Munshi , MD , Dana-Farber Cancer Institute , Boston,  MA

Robert Z. Orlowski , M.D., Ph.D. , The University of Texas MD Anderson Cancer Center , Houston,  TX

Noopur S. Raje , MD , Massachusetts General Hospital Cancer Center , Boston,  MA

Contact:

Sylvia Eriksen , Research To Practice
Email: seriksen@researchtopractice.com

Registration:

http://www.researchtopractice.com/Meetings/FSS2019

Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going

This program is supported by Celgene Corporation

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Regency S

CAR T-cell therapy is at the leading edge of advances in the treatment of relapsed or chemotherapy-refractory B-cell NHL, B-cell precursor ALL, CLL, and multiple myeloma. In this symposium, Stephen J. Schuster, MD; James N. Kochenderfer, MD; Jae Park, MD; and Matthew J. Frigault, MD, will use a case-based approach to examine current and future applications for CAR T-cell therapy across different malignancies, discussing key clinical data and providing practical their expert insights to maximize efficacy while appropriately managing toxicity. Discussion topics include:

• Biologic principles underlying the foundation of CAR T-cell therapy
• CAR T-cell therapy for ALL: maximizing outcomes
• Advances in CAR T-cell therapy for B-cell NHL
• The future of CAR T-cell therapy for myeloma
• Optimizing patient outcomes: identifying and managing CAR T-cell–mediated toxicities
• Future directions, improving access, and overcoming barriers

Chair:

Stephen J. Schuster , MD, Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, PA

Speakers:

Matthew Frigault , MD, MSc , Massachusetts General Hospital Cancer Center , Boston,  MA

James N. Kochenderfer , MD , Center for Cancer Research, National Cancer Institute , Bethesda,  MD

Jae H. Park , MD , Memorial Sloan-Kettering Cancer Ctr. , New York,  NY

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

http://www.clinicaloptions.com/2019OrlandoCART

Advancing the Role of BTK Inhibitors in B-Cell Malignancies: Expert Guidance for Clinical Management

This program is supported by AstraZenca, BeiGene, Ltd. and Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Regency R

This CME-certified satellite symposium will feature the review and discussion of patient case studies and key clinical trial data with renowned clinical experts providing their perspectives on recent advances in the treatment of mantle cell lymphoma, chronic lymphocytic leukemia, and other B-cell malignancies with Bruton’s tyrosine kinase (BTK) inhibitors.

 

Along with the presenting faculty, attendees will be able to vote on how to manage clinically-relevant cases, and will have multiple opportunities to text questions directly to the expert panel for their consideration in a dynamic question and answer format. Critical insights on the similarities and differences among multiple different BTK inhibitors will help prepare attendees to safely and effectively use these agents in their practice. In addition, the faculty will integrate guidance and results from CCO’s exclusive Interactive Decision Support Tool (IDST) for BTK inhibitor adverse event management in the case discussions.

Chair:

Ian W. Flinn , MD, PhD, Sarah Cannon Research Institute, Nashville, TN

Speakers:

Jan A. Burger , MD, PhD , The University of Texas, MD Anderson Cancer Center , Houston,  TX

Alexey Danilov , MD, PhD , Oregon Health & Science University , Portland,  OR

John M. Pagel , MD, PhD, DSc , Swedish Medical Group , Seattle,  WA

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

http://www.clinicaloptions.com/2019OrlandoBTK

Approaches to the Individualized Management of MPNs: Best Practices and Guidance to Optimize Care

This program is supported by Celgene Corporation and CTI BioPharma

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Regency O-Q

This symposium will focus on evolving concepts and practical insights into the diagnosis and management of essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). Each section of the symposium will include a case review and didactic presentation by an expert faculty member followed by a moderated panel discussion and audience Q&A session. Srdan Verstovsek, MD, PhD; Jean-Jacques Kiladjian, MD, PhD; John Mascarenhas, MD; and Raajit K. Rampal, MD, PhD, will discuss each case, including key clinical questions, factors and evidence influencing therapeutic decisions, and their individual treatment recommendations.

 

Throughout the symposium, participants will be able to vote on case scenarios and text questions to the panel for their consideration. Discussion topics include:

• The effect of molecular analysis on the prognosis and treatment of MPNs
• Risk-based stratification and the rationale for risk-adapted therapy for patients with PV and ET
• Risk-based management approaches for patients with MF, with insights into emerging treatments that will likely become part of an increasingly complex treatment algorithm
• Best practice interventions to mitigate treatment-related toxicity or optimize dosing for patients with MPNs

Chair:

Srdan Verstovsek , MD, PhD, University of Texas MD Anderson Cancer Center, Department of Leukemia, Houston, TX

Speakers:

Jean Jacques Kiladjian , MD, PhD , Hopital Saint-Louis , Paris,  France

Raajit K. Rampal , MD, PhD , Memorial Sloan Kettering Cancer Center , New York,  NY

Alessandro M. Vannucchi , MD , University of Florence , Firenze,  Italy

Contact:

For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com

Registration:

http://www.clinicaloptions.com/2019OrlandoMPN

Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy

This program is supported by Kite, A Gilead Company.

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Regency T-V

This live symposium will prepare the hematologists/oncologists in attendance with the knowledge needed to understand and analyze all of the data on CAR T-cell therapy that will be presented during the 2019 ASH annual meeting. Experts on CAR T-cell therapy will discuss the basics of this therapy, clinical trial data for approved and emerging CAR T-cell products, and best practices for managing therapy-related adverse events. During the symposium, faculty will highlight must-see upcoming ASH presentations and posters, highlights of new key data and review of pivotal trials, and practical information about how to identify eligible patients and when to refer to a specialty center.

Chair:

David G. Maloney , MD PhD, Fred Hutchinson Cancer Research Center, Seattle, WA

Speakers:

Marcela V. Maus , MD, PhD , Massachusetts General Hospital, Harvard Medical School , Boston,  MA

Sattva S Neelapu , MD , The University of Texas MD Anderson Cancer Center , Houston,  TX

Contact:

Erin Kiernan , Medscape Education
Email: ekiernan@medscape.net

Registration:

www.medscape.org/sympo/car-t

Moving From Science Fiction to Clinical Reality: Gene Therapy for Beta-Hemoglobinopathies

This program is supported by Bluebird Bio, Inc.

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Orlando Ballroom LMN

A panel of international experts will present key updates in the evolving landscape of gene therapy for beta-thalassemia and SCD. Discussion will include the latest clinical data, strategies for identification of patients who may most benefit from gene therapy, and practical considerations for successful implementation. Furthermore, an integrated video commentary will present the patient voice and perspective on gene therapy for beta-hemoglobinopathies. Designed to blend the latest science with real-world considerations, this session will provide guidance on translating what has been learned through clinical trials on gene therapy into patient care and clinical reality.

Chair:

Elliott Vichinsky , MD, UCSF, UCSF Benioff Children’s Hospital, Oakland, CA

Speakers:

Andreas E. Kulozik , MD, PhD , Department of Pediatric Oncology, Hematology, and Immunology, University of Heidelberg , Heidelberg,  Germany

Deepa Manwani , MD , Children's Hospital at Montefiore , Bronx,  NY

Professor John Rasko , BSc (Med, MBBS (Hons), PhD , Royal Prince Alfred Hospital , Sydney,  Australia

Contact:

Jae Eising , Medscape Education
Email: jeising@medscape.net

Registration:

www.medscape.org/sympo/gene-therapy-beta-heme

MPN Tumor Board: Application of Novel Agents for the Treatment of Polycythemia Vera and Myelofibrosis

This program is supported by Incyte Corporation and PharmaEssentia USA.

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Plaza International I-K

This live CME program to be presented at the 61st American Society of Hematology Annual Meeting and Exposition (ASH) describes current and emerging strategies for the management of patients with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV) and myelofibrosis (MF). Appropriate strategies for identification of patients with varying risk levels of disease, including current strategies for the most effective and most appropriate use of treatment options in specific patient groups, will be reviewed. Appropriate sequencing of agents will also be covered in this program, as well as best practices for the management of patients who experience symptomatic disease progression. Strategies for patient selection based on phenotypic characteristics, clinical trials for combination therapy, and the latest updates from clinical trials across MPNs will be covered in detail through both didactic presentations and case-based tumor board multifaculty discussions.

Chair:

Ronald Hoffman , MD, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY

Speakers:

Rami S. Komrokji , MD , Moffitt Cancer Center , Tampa,  FL

Ann Mullally , MD , Harvard Medical School , Boston,  MA

Abdulraheem Yacoub , MD , University of Kansas Medical Center , Kansas City,  KS

Contact:

Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com

Registration:

www.gotoper.com/go/MPN19

Present Strategies and Future Directions: Treating MDS and MPN

This program is supported by Celgene and Incyte

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Rosen Centre , Grand Ballroom AB

This live, case-based symposium is designed to improve the knowledge and competence of hematologists/oncologists who care for patients with MDS and/or MPNs. Experts will provide clinical pearls and recommendations about how to tailor therapy. New and emerging therapies will also be discussed so hematologists/oncologists are able to incorporate these emerging treatments into clinical practice when they become available.

Chair:

John Mascarenhas , MD, Icahn School of Medicine at Mount Sinai, New York, NY

Speakers:

Prithviraj Bose , MD , MD Anderson Cancer Center , Houston,  TX

Amit Verma , MBBS , Albert Einstein College of Medicine, Montefiore Medical Center , Bronx,  NY

Contact:

Charlene Foroutan , Medscape Oncology
Email: cforoutan@medscape.net

Registration:

www.medscape.org/sympo/mds-mpn

The Evolving Treatment Landscape for Patients with GvHD: More Options, More Decisions, Better Outcomes!

This program is supported by Incyte Corporation, Jazz Pharmaceuticals, Mallinckrodt Pharmaceuticals, and Takeda Oncology.

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Plaza International H

The Evolving Treatment Landscape for Patients With GvHD: More Options, More Decisions, Better Outcomes will highlight current unmet clinical needs and the most recent advances in both acute and chronic graft-versus-host disease (GvHD). This program will feature expert faculty specializing in hematologic oncology and transplantation. Faculty will present the most recent data pertaining to clinical activity of therapeutic agents in development, patient selection, and management of treatment-related adverse events in the GvHD settings. The usefulness of biomarkers that may predict risk of GvHD will be explored, and the importance of prophylaxis for prevention and strategies to mitigate the impact of GvHD on patients will be addressed. This program is designed to be fast-paced and interactive and will optimize learning by using a combination of didactic presentations, challenging case studies involving clinical trial options, panel discussions, and a question-and-answer session. This program offers an exciting opportunity to improve your clinical practice, and we look forward to your participation.

Chair:

Corey S. Cutler , MD, MPH, FRCPC, Dana-Farber Cancer Institute, Boston, MA

Speakers:

James L. M. Ferrara , MD,DSc , Icahn School of Medicine at Mount Sinai , New York,  NY

Shernan Holtan , MD , University of Minnesota , Minneapolis,  MN

Madan Jagasia , MBBS, MS, MMHC , Vanderbilt University Medical Center , Nashville,  TN

Iskra Pusic , MD , Washington University School of Medicine , Saint Louis,  MO

Contact:

Dayna Kleinstein , Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com

Registration:

www.gotoper.com/go/GVHD19

Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies

This program is supported by Actinium Pharmaceuticals Inc., Astellas, Jazz Pharmaceuticals, and Helsinn Healthcare SA.

Friday, December 06, 2019, 6:00 p.m. - 10:00 p.m.
Hyatt Regency Orlando , Plaza International D-F

This live, expert-led, case-based symposium is designed to improve the knowledge and competence of academic- and community-based hematologists/oncologists who care for patients with AML. The cases are the basis for the discussion and will be used to highlight clinical trial data and recent changes in the treatment paradigm. The expert faculty will provide clinical pearls and recommendations for tailoring therapy so clinicians are better able to select therapy that is tailored to patient-and disease-specific characteristics, including cytogenetics and molecular mutations. Experts will also discuss emerging AML therapies and their potential role in the treatment paradigm.

Chair:

Harry P. Erba , MD,PhD, University of Alabama At Birmingham, Durham, NC

Speakers:

Naval G. Daver , MD , University of Texas MD Anderson Cancer Center, Department of Leukemia , Houston,  TX

Alexander E. Perl , MD , University of Pennsylvania , Philadelphia,  PA

Roland P Walter , MD, PhD , University of Washington Medical Center , Seattle,  WA

Contact:

Jae Eising , Medscape Education
Email: jeising@medscape.net

Registration:

www.medscape.org/sympo/aml-updates